<DOC>
	<DOCNO>NCT00925782</DOCNO>
	<brief_summary>To assess compare pharmacokinetics Melphalan HCL Injection ( Propylene Glycol-Free ) versus Alkeran Injection multiple myeloma ( MM ) patient undergo autologous stem cell transplant ( ASCT ) .</brief_summary>
	<brief_title>A Pharmacokinetic Study Melphalan HCL Injection ( Propylene Glycol-Free ) Alkeran Injection Myeloablative Conditioning Multiple Myeloma Patients Undergoing Autologous Transplantation</brief_title>
	<detailed_description>This study multicenter , open-label , randomize , comparative , cross-over study high-dose Melphalan HCl Injection ( Propylene Glycol-Free ) Alkeran Injection conduct 24 patient symptomatic MM qualify ASCT . During Study Period , patient randomize receive 100mg/m2 either Melphalan HCl Injection ( Propylene Glycol-Free ) Alkeran Injection Day -3 alternate drug product Day -2 . Blood sample pharmacokinetic ( PK ) evaluation withdrawn indwell i.v . cannula day melphalan dose ( Day -3 Day -2 ) . Following one day rest myeloablative conditioning ( Day -1 ) , patient receive autologous graft .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Patients symptomatic MM require treatment diagnosis anytime thereafter . Patients MM qualify ASCT therapy receive appropriate primary induction therapy transplantation . Adult patient ( ≥ 18 year old ) 70 year age young time transplant ; patient great 70 year age may qualify casebycase basis patient meet local institutional criterion receive total melphalan dose 200 mg/m2 condition regimen approve Medical Monitor . Patients adequate autologous graft define unmanipulated , cryopreserved , peripheral blood stem cell graft contain least 2 × 106 CD34+ cells/kg base upon patient weight . Patients adequate organ function measure : Cardiac : Left ventricular ejection fraction rest &gt; 40 % ( document within 12 week prior Day 3 ) . Hepatic : Bilirubin &lt; 2 × upper limit normal ( ULN ) ALT/AST &lt; 3 × ULN . Renal : Creatinine clearance &gt; 40 mL/minutes ( measure calculated/estimated ) . Pulmonary : DLCO , FEV1 , FVC &gt; 50 % predict value ( correct Hgb ) O2 saturation &gt; 92 % room air ( document within 12 week prior Day 3 ) Patients never advance beyond Stage 1 MM since diagnosis . Patients previously receive one autologous stem cell transplant . Patients plasma cell leukemia . Patients MM systemic AL amyloidosis . ECOG performance status ≥2 . Patients uncontrolled hypertension . Patients active bacterial , viral , fungal infection . Patients prior malignancy except resect basal cell carcinoma treat cervical carcinoma situ . Cancer treat curative intent &gt; 5 year previously allow . Cancer treat curative intent &lt; 5 year previously allow unless approve medical monitor . Female patient pregnant ( positive ßHCG ) breastfeeding . Female patient childbearing potential unwilling use adequate contraceptive technique 1 month follow study treatment Melphalan HCl Injection ( Propylene GlycolFree ) . Patients seropositive HIV . Patients unwilling provide informed consent . Patients receive concurrent anticancer therapy ( include chemotherapy , radiation , hormonal treatment , immunotherapy , exclude corticosteroid ) within 21 day prior ASCT , plan receive treatment prior study discharge . Patients concurrently participate clinical study . Patients hypersensitive intolerant component study drug formulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>autologous stem cell transplantation</keyword>
</DOC>